Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. - Wikidata - awgldk - TriplyDB

Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.

Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.

http://www.wikidata.org/entity/Q34734292

about

Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management Management of the older person with atrial fibrillation.Atrial Fibrillation: The New Epidemic of the Ageing World The case for inpatient initiation of antiarrhythmic therapy.Antiarrhythmic drugs for atrial fibrillation.Pharmacological management of atrial fibrillation: one, none, one hundred thousand.Treating critical supraventricular and ventricular arrhythmias.Therapy of atrial fibrillation: rhythm control versus rate control.Pure class III antiarrhythmic drugs: focus on dofetilide.Pharmacotherapy of atrial fibrillation.Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation.Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials.Special problems with antiarrhythmic drugs in the elderly: safety, tolerability, and efficacy.Antiarrhythmic drugs: new agents and evolving concepts.Emergency management of atrial fibrillation Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.Review of the current management of atrial fibrillation.Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil.Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation.Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility.Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits.Long QT syndrome: reduced repolarization reserve and the genetic link.Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients--a clinical framework Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter.Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview.Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction.Conversion of Persistent Atrial Fibrillation After Radiofrequency Ablation by Ibutilide.Predictors of long-term maintenance of normal sinus rhythm after successful electrical cardioversion.Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation.Keep the QT interval: it is a reliable predictor of ventricular arrhythmias.Cardioversion of atrial fibrillation and subsequent maintenance of sinus rhythm.Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?Searching for the Ideal Class III Antiarrhythmic Agent: How Pure Should they Be?Ibutilide for the Cardioversion of Paroxysmal Atrial Fibrillation during Radiofrequency Ablation of Supraventricular Tachycardias.Safety and effectiveness of ibutilide in a community hospital.Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies.Ibutilide-induced alterations in electrocardiographic and spatial vectorcardiographic descriptors of ventricular repolarization.

P2860

Q26747032-8AA1747D-3366-42FF-A16A-927C18510181 Q33144789-DDEE8E9A-2351-4FBD-8B3A-C905A76C9D68 Q33168630-D84DBB12-916B-40BF-BC09-3B6E53BF5755 Q33598024-CFE3F4AB-1F7D-47AF-9705-364506991624 Q33821199-4A2D8655-72E2-4E7D-A585-2EFEC826D6D3 Q33902193-418D1724-5024-498E-B9F9-740593A2EF65 Q33909242-E93752E0-87AF-422E-A991-B7D53B12E20F Q33931009-212C7A8C-2C3B-4D57-8E03-C4EE0C5CB75A Q34126027-7B1D4E9B-9584-443D-8182-9DD063E9DE37 Q34182375-8E09B510-250E-452A-A35C-54FE0E4AD4E2 Q34422636-16AC8A13-A9B6-494D-A405-AB6995ADA714 Q34491925-838E193F-E544-47D0-B085-3D5A545C8C4A Q34496116-3E4F36E1-FE69-4CDF-807E-B2F2D9F55395 Q34989738-5E500647-CF26-4117-891E-E6323386DB54 Q35073365-07078C67-F3CC-45C9-A4BA-0EB39ADDBA64 Q35168643-B8AC8962-4A80-4E67-8585-CD68B7DAC497 Q35368049-F3F6E065-CD13-495C-AD02-7FA5583A5ADA Q35574957-2B0FD4E1-90AB-4071-9CC2-8E874DF49E2F Q35582341-72E9C4A8-E83B-49C3-BA8C-479650C204F6 Q35771784-39893337-BD99-4CD7-B2F1-369238E31566 Q35814463-571363E3-AA15-46B3-A807-77A4C1C19139 Q35892164-97BDEC24-AD8E-48B9-B1FD-E43E4DE3197E Q36216795-F2585BB0-AB11-4D1E-8671-F12F86853D20 Q36335258-2A9633A3-B40D-4D9A-AA33-FCBA645665BD Q37013160-3E3A4A56-C4ED-41C6-814E-11BFF7B87BDD Q37018366-7C18EFE6-22D5-48A2-938F-4158B9FFE0A4 Q37098991-DE60AB74-6A41-4422-9525-DAED20EDFCD8 Q37378050-EE35A0EA-3994-409B-9A3A-B70B24A908BD Q37495653-CA7F05EA-0A9C-4FA7-9BF3-AFBE60FD8B4F Q38202066-7860AD88-29C6-4198-9675-6288743446B8 Q38853630-98B45E95-46B7-4547-A9F2-96611A90B93B Q39018169-B13327DC-93EB-4826-B07C-CC411E85CC93 Q40878614-A7BE6421-6EA7-4B45-AD31-32BE8B1236C3 Q41720833-728AAC60-D7DA-4B34-8B5F-242BDD7C7A33 Q41720852-C1E2862F-2F41-4686-AAB3-5042829C5DDD Q42126821-3F68B81C-A847-4A0C-8368-044768D08E22 Q43580197-4BD48F14-22AF-4D11-B545-1850A15E3D84 Q44360562-6E1B7E9C-0E32-41B7-9DD6-3B8417597476 Q44844508-D602BCD5-BC7E-4F19-8B63-36857E81B4E0 Q44966752-B778F5FA-F9E3-4C81-B1F4-B95EB4A921D7

P2860

Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.

http://www.wikidata.org/entity/Q34734292

description

1996 nî lūn-bûn

@nan

1996 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Efficacy of intravenous ibutil ...... lutter: a dose-response study.

@ast

Efficacy of intravenous ibutil ...... lutter: a dose-response study.

@en

Efficacy of intravenous ibutil ...... lutter: a dose-response study.

@nl

type

label

Efficacy of intravenous ibutil ...... lutter: a dose-response study.

@ast

Efficacy of intravenous ibutil ...... lutter: a dose-response study.

@en

Efficacy of intravenous ibutil ...... lutter: a dose-response study.

@nl

prefLabel

Efficacy of intravenous ibutil ...... lutter: a dose-response study.

@ast

Efficacy of intravenous ibutil ...... lutter: a dose-response study.

@en

Efficacy of intravenous ibutil ...... lutter: a dose-response study.

@nl

P1433

Q34734292-392CD43F-B7E3-4BFF-9B39-AE6E325D3A86

P1476

Q34734292-E9A99BFB-2C94-4B82-BADC-A49EF67056BF

P2093

Q34734292-1E54392A-CE5A-4541-9442-E6AC5DAAEE68

Q34734292-2588D1B8-533B-4051-836E-A680167620A9

Q34734292-5A1233EE-D59B-427F-AC30-1516DDDDF08F

Q34734292-66D57E1A-6751-49F6-888F-04259FF51A48

Q34734292-9794277E-176E-4113-BB6A-8D784F790DB3

Q34734292-B96D98AB-FF65-4206-B353-6AB3D37CF112

Q34734292-DFCCC8DA-3DBA-4AA2-908D-5FD1237E3781

Q34734292-EA51B69B-0BDF-4B6A-B573-93D9EEAE31C5

Q34734292-EC80781F-719E-4BE3-9350-61D87D021F7E

Q34734292-F2FAAA70-F496-4F8F-9DE2-8FEFC8C3B961

P304

Q34734292-4C9481AB-6885-45D5-A377-DA4651559140

P31

Q34734292-8703621D-3177-44CA-8F36-9306445B6CAC

P356

Q34734292-B69DA907-4441-4FDB-BDAC-1177F5312CC1

P407

Q34734292-017B086F-306A-42CE-B1CA-7176C78C885C

P433

Q34734292-E80097F6-976D-48F4-ACCA-1DAC8AA213FA

P478

Q34734292-364926C3-DA50-4C40-82EF-0BF16832ECA7

P577

Q34734292-6E46B1BE-BF8E-4149-988A-F5DCACDD16DC

P5875

Q34734292-F724C390-906F-4807-B104-F8011EDA77F6

P698

Q34734292-EC4190AF-4E20-4CF6-812E-862C92AE98CF

P921

Q34734292-ADC09420-45C4-4014-B804-C59CB8AD4006

P356

0735-1097(96)00121-0

P1433

Journal of the American College of Cardiology

P1476

Efficacy of intravenous ibutil ...... lutter: a dose-response study.

@en

P2093

Ellenbogen KA

http://www.w3.org/2001/XMLSchema#string

Meissner MC

http://www.w3.org/2001/XMLSchema#string

Perry KT

http://www.w3.org/2001/XMLSchema#string

Sager PT

http://www.w3.org/2001/XMLSchema#string

Stambler BS

http://www.w3.org/2001/XMLSchema#string

Vanderlugt JT

http://www.w3.org/2001/XMLSchema#string

Wakefield LK

http://www.w3.org/2001/XMLSchema#string

Wesley RC Jr

http://www.w3.org/2001/XMLSchema#string

Wood MA

http://www.w3.org/2001/XMLSchema#string

Zoble RG

http://www.w3.org/2001/XMLSchema#string

P304

130-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/0735-1097(96)00121-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

1996-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232356357

http://www.w3.org/2001/XMLSchema#string

P698

8752805

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation